India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.
The company posted net profit of Rs.321 crores for the period ended June 30, 2020.
The US business faced price erosion due to increased competition.
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
The company has reported total income of Rs.355.43 crores during FY 2020-21
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated
